Detailed description page of SalivaDB

This page displays user query in tabular form.

SAL_16455 details
Primary information
SALIDSAL_16455
Biomarker nameL-proline
Biomarker TypeNA
Sampling MethodFifty-nine (59) participants, aged between 35 and 65 years, were selected from the Department of Otolaryngology, DEA III Liv. Nocera-Pagani, Salerno, from July 2014 to July 2016.
Collection MethodSaliva samples were collected from male and female according to the standard operating procedure (SOP) for metabolomic-grade saliva samples
Analysis MethodH-NMR
Collection SiteWhole Saliva
Disease CategoryTumor
Disease/ConditionSalivary Gland Tumor
Disease SubtypeParotid Tumor
Fold Change/ ConcentrationNA
Up/DownregulatedIncrease
ExosomalNA
OrganismHomo sapiens
PMID30138814
Year of Publication2018
Biomarker ID145742
Biomarker CategoryMetabolite
SequenceC1C[C@H](NC1)C(=O)O
Title of studySaliva of patients affected by salivary gland tumour: An NMR metabolomics analysis
Abstract of studyCancers affecting the salivary glands have been an increasing incidence. Salivary gland cancer is not detected until it reaches an advanced stage, which would generally result in a poor prognosis and survival rate. Therefore, early detection as well as the screening of high risk populations with precancerous lesions remains an unmet medical need. In the present work, we present a NMR-based metabolomic study of the saliva of patients suffering from salivary gland tumours. Analysis of data was done using a combined approach based on PRICONA quantitative analysis and statistical multivariate analysis. Interestingly, both the analytical methods indicate that individuals affected by parotid tumour have a characteristic metabolomic profile characterized by abnormalities in the concentration of several aminoacids. Among these the most significant are those relative to Alanine and Leucine suggestive of an alteration in the metabolic pathways of glycogenic aminoacids and ketone bodies. Our data, describing the preliminary metabolomics fingerprint of parotid tumour, are consistent with the recent view that oncogenic signalling corresponds to alteration in the metabolism of nutrient pull (Vander Heiden et al., 2009), rather than to a single metabolite.